Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Capstone Therapeutics ( (CAPS) ) has issued an update.
On December 15, 2025, Capstone Holding Corp. released an investor presentation detailing its 2026 strategy, emphasizing its growth through acquisitions and organic expansion. The company has successfully integrated recent acquisitions, achieving a $70 million revenue run rate, and is on track to meet its $100 million target by 2026. This strategy positions Capstone to capitalize on deferred construction demand, enhancing its market presence and shareholder value.
The most recent analyst rating on (CAPS) stock is a Hold with a $0.91 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.
Spark’s Take on CAPS Stock
According to Spark, TipRanks’ AI Analyst, CAPS is a Neutral.
Capstone Therapeutics’ overall stock score is primarily impacted by its weak financial performance and valuation, reflecting significant risks. However, recent corporate events provide a positive outlook, potentially improving future revenue and financial stability. Technical analysis shows a bearish trend, but not excessively so, contributing to a moderate overall score.
To see Spark’s full report on CAPS stock, click here.
More about Capstone Therapeutics
Capstone Holding Corp. is a leading distributor of building products in North America. The company has expanded from a single-site distributor to a platform serving over 32 states and Canada through organic growth and strategic acquisitions. Capstone aims to reach a $100 million revenue run rate by 2026, having already achieved $70 million in pro forma revenue.
Average Trading Volume: 932,329
Technical Sentiment Signal: Sell
Current Market Cap: $7.21M
See more insights into CAPS stock on TipRanks’ Stock Analysis page.